References
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Internet]. 2020 Feb 15 [cited 2021 Jan 21];395(10223):497–506. Available from. ;():. /pmc/articles/PMC7159299/?report=abstract
- Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect [Internet]. 2020 Jun 1 [cited 2021 Jan 21];80(6):656–665. Available from: /pmc/articles/PMC7151416/?report=abstract
- Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 2020 Apr 30 [cited 2021 Jan 21];382(18):1708–1720. Available from: /pmc/articles/PMC7092819/?report=abstract
- Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging [Internet]. J Clin Investigat Am Soc Clin Investigat. cited 2021 Jan 21. p. 2202–2205. Available from. ; 2020;130 5: https://doi.org/10.1172/JCI137647.
- Meidaninikjeh S, Sabouni N, Marzouni HZ, et al. Monocytes and macrophages in COVID-19: Friends and foes. Life Sci [Internet]. 2021 Mar [cited 2021 Jan 21];269:119010. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0024320520317707
- Catanzaro M, Fagiani F, Racchi M, et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 [Internet]. Vol. 5, Signal Transduct Target Ther. Springer Nature; 2020 [cited 2021 Jan 21]. Available from: https://pmc/articles/PMC7255975/?report=abstract 1
- Channappanavar R, and Perlman S Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Semin Immunopathol ; 2017 39(5):529-539. Available from: https://pmc/articles/PMC7079893/?report=abstract doi:https://doi.org/10.1007/s00281-017-0629-x
- Shimabukuro-Vornhagen A, Gödel P, and Subklewe M, et al. Cytokine release syndrome [Internet] Journal for ImmunoTherapy of Cancer. 2018 [cited 2021 Jan 21]. 6:https://pmc/articles/PMC6003181/?report=abstract
- Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood [Internet]. 2014 Jul 10 [cited 2021 Jan 21];124(2):188–195. Available from: /pmc/articles/PMC4093680/?report=abstract
- Zhou Y, Fu B, and Zheng X Pathogenic Tcells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients Natl Sci Rev. 2020; 7(6):998–1002 doi:https://doi.org/10.1093/nsr/nwaa041.
- Conti P, Caraffa A, Gallenga CE, et al. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. J Biol Regul Homeost Agents [Internet]. 2020 Nov 1 [cited 2021 Dec 23];34(6):1971–1975. Available from: https://pubmed.ncbi.nlm.nih.gov/33016027/
- Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents [Internet]. 2020 Mar 1 [cited 2021 Dec 23];34(2):327–331. Available from: https://pubmed.ncbi.nlm.nih.gov/32171193/
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.J Am Med Assoc [Internet]. 2020 Mar 17 [cited 2021 Jan 21];323(11):1061–1069. Available from: /pmc/articles/PMC7042881/?report=abstract
- Coomes EA, Haghbayan H. A systematic review and meta-analysis [Internet]. Rev Med Virol John Wiley and Sons Ltd. 2020 [cited 2021 Jan 21];30(6):1–9. Available from: /pmc/articles/PMC7460877/?report=abstract
- Theoharides TC, Conti P Be aware of SARS-CoV-2 spike protein: There is more than meets the eye. J Biol Regul Homeost Agents [Internet]. 2021 May 1 [cited 2021 Dec 23];35(3):833–838. Available from: https://pubmed.ncbi.nlm.nih.gov/34100279/
- Ciprandi G, La Mantia I, Brunese FP, et al. Hypertonic saline with xylitol and hyaluronate may shorten the viral shedding duration in asymptomatic COVID-19 positive subjects: a pilot study. J Biol Regul Homeost Agents [Internet]. 2021 May 1 [cited 2021 Dec 23];35(3):1151–1154. Available from: https://pubmed.ncbi.nlm.nih.gov/34229425/
- Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal [Internet]. J Heart Lung Transplant Elsevier USA. 2020 [cited 2021 Jan 21];39(5):405–407. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118652/
- Juul S, Nielsen EE, Feinberg J, et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One [Internet]. 2021 Mar 1 [cited 2021 Apr 15];16(3 March). Available from: https://pubmed.ncbi.nlm.nih.gov/33705495/ e0248132
- Jones CW, Woodford AL, Platts-Mills TF Characteristics of COVID-19 clinical trials registered with clinicaltrials.gov: Cross-sectional analysis. BMJ Open [Internet]. 2020 Sep 17 [cited 2021 Jan 13];10(9). Available from: https://pubmed.ncbi.nlm.nih.gov/32948577/
- Mayer CS, Huser V Computerized monitoring of COVID-19 trials, studies and registries in ClinicalTrials.gov registry. PeerJ [Internet]. 2020 Oct 23 [cited 2021 Jan 13];8. Available from: https://pubmed.ncbi.nlm.nih.gov/33150094/
- Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action [Internet]. Autoimmun Rev. 2020 [[cited 2021 Jan 13]. Available from];19(7):102554. Elsevier B.V. https://pubmed.ncbi.nlm.nih.gov/32380316/
- Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun [Internet]. 2021 Mar 1 [cited 2021 Apr 15];118. Available from: https://pubmed.ncbi.nlm.nih.gov/33524876/ 102598
- Ranjan Paul S, Roy R, Maiti R, et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. Abhishake Lahiri 2# [Internet]. 2020 Oct 7 [cited 2021 Jan 13]; (3):4. Available from: https://doi.org/10.1101/2020.09.21.20199109
- Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. J Am Med Assoc [Internet]. 2020 Aug 4 [cited 2021 Jan 12];324(5):460–470. Available from: /pmc/articles/PMC7270883/?report=abstract
- Salazar E, Kuchipudi SV, Christensen PA, et al. Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest [Internet]. 2020 Dec 1 [cited 2021 Jan 13];130(12):6728–6738. Available from: https://pubmed.ncbi.nlm.nih.gov/32910806/
- Perreault J, Tremblay T, Fournier MJ, et al. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset [Internet]. Blood. 2020[cited 2021 Jan 13];136(22):2588–2591. Available from. American Society of Hematology. /pmc/articles/PMC7714093/?report=abstract
- Boonyaratanakornkit J, Morishima C, Selke S, et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. J Clin Invest [Internet]. 2021 Feb 1 [cited 2021 Apr 15];131(3). Available from: https://pubmed.ncbi.nlm.nih.gov/33320842/
- Bradfute SB, Hurwitz I, Yingling AV, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019. J Infect Dis [Internet]. 2020 Oct 13 [cited 2021 Jan 13];222(10):1620–1628. Available from: https://pubmed.ncbi.nlm.nih.gov/32779705/
- Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin Internet]. 2020 [cited 2021 Jan 13];72(3):159–164. Available from. https://pubmed.ncbi.nlm.nih.gov/32584322/
- Salazar E, Perez KK, Ashraf M, et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol [Internet]. 2020 Aug 1 [cited 2021 Jan 13];190(8):1680–1690. Available from: https://pubmed.ncbi.nlm.nih.gov/32473109/
- Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci [Internet]. 2020 Oct 1 [cited 2021 Jan 13];59(5):102875. Available from: /pmc/articles/PMC7362821/?report=abstract
- Shenoy AG, Hettinger AZ, Fernandez SJ, et al. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol [Internet]. 2021 Feb 1 [cited 2021 Apr 15];192(4):706–713. Available from: https://pubmed.ncbi.nlm.nih.gov/33482025/
- Allahyari A, Seddigh-Shamsi M, Mahmoudi M, et al. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome. Int Immunopharmacol [Internet]. 2021 Apr 1 [cited 2021 Apr 15];93. Available from: https://pubmed.ncbi.nlm.nih.gov/33582019/ 107239
- Shao S, Wang Y, Kang H, et al. Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis. Int J Infect Dis. [Internet]. 2021 Jan 1 [cited 2021 Apr 15];102:397–411. Available from;:.https://pubmed.ncbi.nlm.nih.gov/33002611/
- Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med [Internet]. 2021 Feb 18 [cited 2021 Apr 15];384(7):610–618. Available from: https://pubmed.ncbi.nlm.nih.gov/33406353/
- Bratcher-Bowman N Convalescent Plasma EUA Letter of Authorization March 9, 2021 [Internet]. 2021 [cited 2021 Apr 19]. Available from: https://www.govinfo.gov/content/pkg/FR-2020-04-01/pdf/2020-06905.pdf.
- Chai KL, Valk SJ, Piechotta V, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane database Syst Rev [Internet]. 2020 Oct 12 [cited 2021 Jan 13];10(10):CD013600. Available from: https://www.cochranelibrary.com/cdsr/doi/https://doi.org/10.1002/14651858.CD013600.pub3/full
- Axfors C, Janiaud P, Schmitt AM, et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis [Internet]. 2021 Dec 1 [cited 2021 Dec 26];21(1):1–23. Available from: https://bmcinfectdis.biomedcentral.com/articles/https://doi.org/10.1186/s12879-021-06829-7
- Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment with Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis [Internet]. JAMA. 2021[[cited 2021 Apr 15]. Available from];325(12):1185. https://pubmed.ncbi.nlm.nih.gov/33635310/
- Balcells ME, Rojas L, Le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med [Internet]. 2021 Mar 3 [cited 2021 Apr 15];18(3):e1003415. Available from: https://pubmed.ncbi.nlm.nih.gov/33657114/
- Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ [Internet]. 2020 Oct 22 [cited 2021 Jan 13];371. Available from: /pmc/articles/PMC7578662/?report=abstract
- Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med [Internet]. 2021 Feb 18 [cited 2021 Apr 15];384(7):619–629. Available from: https://pubmed.ncbi.nlm.nih.gov/33232588/
- Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med [Internet]. 2021 Nov 1 [cited 2021 Dec 26];27(11):2012–2024. Available from: https://pubmed.ncbi.nlm.nih.gov/34504336/
- Abani O, Abbas A, Abbas F, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet (London, England) [Internet]. 2021 May 29 [cited 2021 Dec 26];397(10289):2049–2059. Available from: https://pubmed.ncbi.nlm.nih.gov/34000257/
- Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Intern Med [Internet]. 2021 Dec 13; Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2787090
- Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med [Internet]. 2021 Nov 18 [cited 2021 Dec 26];385(21):1951–1960. Available from: https://pubmed.ncbi.nlm.nih.gov/34407339/
- Joyner MJ, Carter RE, and Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 N Engl J Med. [Internet]. 2021 Jan 13 [cited 2021 Sep 7];384(11):1015–1027. [Internet]. 2021 Jan 13. ; ():.
- Yaqinuddin A, Rahman Ambia A, Atef Elgazzar T, et al. Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19-A theoretical perspective. Medical Hypotheses. 2021 [cited 2021 Sep 7]; Available from;151:110592. DOI:https://doi.org/10.1016/j.mehy.2021.110592.
- Jamaati H, Dastan F, Tabarsi P, et al. A fourteen-day experience with coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS): An Iranian treatment protocol. Iran J Pharm Res [Internet]. 2020 Dec 1 [cited 2021 Jan 14];19(1):31–36. Available from: /pmc/articles/PMC7462513/?report=abstract
- Ali S, Luxmi S, Anjum F, et al. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. BioMed Central Ltd 2020 [cited 2021 Jan 14]. Available from; 21(1).Internet https://pubmed.ncbi.nlm.nih.gov/33138867/
- Çolak M, Kalemci S, Sarıhan A. Treatment of a case with COVID-19 administering intravenous immunoglobulin. J Glob Antimicrob Resist. 2020 Dec 1; 24:106–107.https://doi.org/10.1016/j.jgar.2020.12.003
- Xie Y, Cao S, Dong H, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect [Internet]. 2020 Aug;81(2):318–356. Available from].
- Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. Internet]. 2020 [cited 2021 Jan 14];7(3):1–6. Available from;: https://pubmed.ncbi.nlm.nih.gov/32258207/
- Shao Z, Feng Y, Zhong L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunol. Internet]. 2020 [cited 2021 Jan 14];9(10). Available from. https://pubmed.ncbi.nlm.nih.gov/33082954/
- Herth FJF, Sakoulas G, Haddad F Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series. Respiration [Internet]. 2020 [cited 2021 Jan 14]; Available from: https://pubmed.ncbi.nlm.nih.gov/33316806/
- Huang C, Fei L, Li W, et al. Efficacy Evaluation of Intravenous Immunoglobulin in Non-severe Patients with COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching. Int J Infect Dis [Internet]. 2021 Jan 9 [cited 2021 Jan 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33434674
- Zhou Z-G, Xie S-M, Zhang J, et al. Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy. 2020 Mar 4 [cited 2021 Jan 14]; Available from: https://europepmc.org/article/ppr/ppr116345
- Gharebaghi N, Nejadrahim R, Mousavi SJ, et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis [Internet]. 2020 Dec 1 [cited 2021 Jan 14];20(1). Available from: /pmc/articles/PMC7576972/?report=abstract
- Sakoulas G, Geriak M, Kullar R, et al. Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019. Crit Care Explor [Internet]. 2020 Nov 16 [cited 2021 Jan 14];2(11):e0280. Available from: https://pubmed.ncbi.nlm.nih.gov/33225306/
- Cao W, Liu X, Hong K, et al. High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. Front Immunol [Internet]. 2021 Feb 19 [cited 2021 Apr 15];12. Available from: https://pubmed.ncbi.nlm.nih.gov/33679771/
- Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol [Internet]. 2021 Jan 1 [cited 2021 Apr 15];90. Available from: https://pubmed.ncbi.nlm.nih.gov/33214093/ 107205
- Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial. J Am Med Assoc [Internet]. 2021 Feb 16 [cited 2021 Apr 16];325(7):632–644. Available from: https://pubmed.ncbi.nlm.nih.gov/33475701/
- Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med [Internet]. 2021 Oct 7 [cited 2021 Dec 26];385(15):1382–1392. Available from: https://pubmed.ncbi.nlm.nih.gov/34260849/
- FDA. Fact sheet for health care providers. Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. [Internet]. [cited 2021 Apr 16]. Available from: https://www.cdc.gov/growthcharts/clinical_charts.htm,
- Lilly News Release. Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 | Eli Lilly and Company [Internet]. [cited 2021 Apr 16]. Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced
- ACTIV-3/TICO LY-CoV555 Study Group, Lundgren, Jens D , Grund, Birgit et al A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med [Internet]. 2021 Mar 11 [cited 2021 Apr 16];384(10):905–914. [Internet]. 2021 Mar 11: https://pubmed.ncbi.nlm.nih.gov/33356051/
- Cohen MS, Nirula A, Mulligan MJ, et al. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA [Internet]. 2021 Jul 6 [cited 2021 Dec 26];326(1):46–55. Available from: https://pubmed.ncbi.nlm.nih.gov/34081073/
- Gormley A. Bamlanivimab and Etesevimab EUA Letter of Authorization (FDA) . 2021.
- FDA. Fact sheet for health care providers. Emergency Use Authorization (EUA) of casirivimab and imdevimab [Internet]. [cited 2021 Apr 16]. Available from: https://www.cdc.gov/growthcharts/clinical_charts.htm,
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med [Internet]. 2021 Jan 21 [cited 2021 Apr 16];384(3):238–251. Available from: https://pubmed.ncbi.nlm.nih.gov/33332778/
- FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COV TM (casirivimab and imdevimab). 2021 [cited 2021 Sep 7]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med [Internet]. 2021 Dec 2 [cited 2021 Dec 26];385(23):e81. Available from: https://pubmed.ncbi.nlm.nih.gov/34587383/
- Group RC, Horby PW, Mafham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Internet]. 2021 Jun 16 [cited 2021 Dec 26];2021.Jun.15.21258542. Available from: https://www.medrxiv.org/content/https://doi.org/10.1101/2021.06.15.21258542v1
- Ash J, Leavitt R, Dietrich T, et al. Real world utilization of REGEN-COV2 at a community hospital. Am J Emerg Med [Internet]. 2021 Dec 1 [cited 2021 Dec 26];50:129–131. Available from: https://pubmed.ncbi.nlm.nih.gov/34364110/
- Dhand A, Lobo SA, Wolfe K, et al. Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience. Transplantation [Internet]. 2021 Jul 1 [cited 2021 Dec 26];105(7):e68–9. Available from: https://journals.lww.com/transplantjournal/Fulltext/2021/07000/Casirivimab_imdevimab_for_Treatment_of_COVID_19_in.30.aspx
- Sidebottom DB, Gill D Ronapreve for prophylaxis and treatment of covid-19. BMJ [Internet]. 2021 Sep 2 [cited 2021 Dec 26];374. Available from: https://www.bmj.com/content/374/bmj.n2136
- Lake DH GSK Sotrovimab Letter Of Authorization 05262021. 2021 [cited 2021 Sep 7]; Available from: www.sotrovimab.com
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med [Internet]. 2021 Nov 18 [cited 2021 Dec 26];385(21):1941–1950. Available from: https://pubmed.ncbi.nlm.nih.gov/34706189/
- Shuai H, Chu H, Hou Y, et al. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer. J Infect [Internet]. 2020 Oct 1 [cited 2021 Jan 19];81(4):e1–10. Available from: https://pubmed.ncbi.nlm.nih.gov/32707230/
- Zheng F, Zhou Y, Zhou Z, et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. Int J Infect Dis [Internet]. 2020 Oct 1 [cited 2021 Jan 19];99:84–91. Available from: https://pubmed.ncbi.nlm.nih.gov/32758689/
- Li C, Luo F, Liu C, et al. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. Ann Med. Internet]. 2021 [cited 2021 Apr 16];53(1):391–401. Available from;: https://pubmed.ncbi.nlm.nih.gov/33620016/
- Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun [Internet]. 2021 Dec 30 [cited 2021 Apr 16];12(1):1967. Available from: http://www.nature.com/articles/s41467-021-22177-1
- Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021 [[cited 2021 Apr 16]; Available from];9(5):498–510. Internet: https://pubmed.ncbi.nlm.nih.gov/33556319/
- Walz L, Cohen AJ, Rebaza AP, et al. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infect Dis [Internet]. 2021 Dec 1 [cited 2021 Apr 16];21(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33430799/
- Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med [Internet]. 2021 Feb 1 [cited 2021 Apr 16];9(2):196–206. Available from: https://pubmed.ncbi.nlm.nih.gov/33189161/
- Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother [Internet]. 2020 Sep 1 [cited 2021 Jan 19];64(9). Available from: https://pubmed.ncbi.nlm.nih.gov/32661006/
- Dastan F, Nadji SA, Saffaei A, et al. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol [Internet]. 2020 Aug 1 [cited 2021 Jan 19];85. Available from: https://pubmed.ncbi.nlm.nih.gov/32544867/
- Baghaei P, Dastan F, Marjani M, et al. Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of severe COVID-19 infected inpatients. Int Immunopharmacol. Internet]. 2020 Dec [cited 2021 Jan 19];92:107329. Available from ;:. https://pubmed.ncbi.nlm.nih.gov/33412395/
- Alavi Darazam I, Hatami F, Mahdi Rabiei M, et al. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. Int Immunopharmacol [Internet]. 2021 Oct 1 [cited 2021 Dec 26];99. Available from: https://pubmed.ncbi.nlm.nih.gov/34224994/ 107916
- Ader F, Peiffer-Smadja N, Poissy J, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect [Internet]. 2021 Dec 1 [cited 2021 Dec 26];27(12):1826–1837. Available from: https://pubmed.ncbi.nlm.nih.gov/34048876/
- Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep [Internet]. 2021 Dec 1 [cited 2021 Dec 26];11(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33850184/
- Mary A, Hénaut L, Macq PY, et al. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience. Front Pharmacol [Internet]. 2020 Nov 30 [cited 2021 Jan 19];11. Available from: https://pubmed.ncbi.nlm.nih.gov/33329000/
- Khamis F, Al Naabi H, Al Lawati A, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis [Internet]. 2021 Jan 1 [cited 2021 Jan 19];102:538–543. Available from: https://pubmed.ncbi.nlm.nih.gov/33181328/
- Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol [Internet]. 2020 Nov 1 [cited 2021 Jan 19];88. Available from: https://pubmed.ncbi.nlm.nih.gov/32862111/
- Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet [Internet]. 2020 May 30 [cited 2021 Jan 19];395(10238):1695–1704. Available from: https://pubmed.ncbi.nlm.nih.gov/32401715/
- Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Front Immunol [Internet]. 2020 May 15 [cited 2021 Jan 19];11:1061. Available from: /pmc/articles/PMC7242746/?report=abstract
- Rui HS, Yan R, Yan ZS, et al. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. J Zhejiang Univ Sci B [Internet]. 2020 Aug 1 [cited 2021 Jan 19];21(8):628–636. Available from: https://pubmed.ncbi.nlm.nih.gov/32748578/
- Wang N, Zhan Y, Zhu L, et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe [Internet]. 2020 Sep 9 [cited 2021 Jan 19];28(3):455–464.e2. Available from: https://pubmed.ncbi.nlm.nih.gov/32707096/
- Wang B, Li D, Liu T, et al. Subcutaneous injection of IFN alpha-2b for COVID-19: An observational study. BMC Infect Dis [Internet]. 2020 Oct 2 [cited 2021 Jan 19];20(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33008327/
- Bhushan BLS, Wanve S, Koradia P, et al. Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. Int J Infect Dis [Internet]. 2021 Oct 1 [cited 2021 Dec 26];111:281–287. Available from: https://pubmed.ncbi.nlm.nih.gov/34428542/
- Meng Z, Wang T, Chen L, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem [Internet]. 2021 May 13 [cited 2021 Dec 26];21(10):920–927. Available from: https://pubmed.ncbi.nlm.nih.gov/33970846/
- Li C, Luo F, Liu C, et al. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. Ann Med Internet]. 2021 [cited 2021 Dec 26];53(1):391–401. Available from. ;:. https://pubmed.ncbi.nlm.nih.gov/33620016/
- Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis [Internet]. Eur Cytokine Netw John Libbey. 2020 [cited 2021 Jan 13];31(2):44–49. Available from: https://pubmed.ncbi.nlm.nih.gov/32933891/
- Ivan Hariyanto T, Kurniawan A Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection. J Med Virol [Internet]. 2021 Mar 1 [cited 2021 Apr 16];93(3):1832–1836. Available from: https://pubmed.ncbi.nlm.nih.gov/33241872/
- Ulhaq ZS, Soraya GV Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia. Med Clin (Barc) [Internet]. 2020 Dec 24 [cited 2021 Jan 13];155(12):548–556. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351402/
- Malekzadeh R, Abedini A, Mohsenpour B, et al. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. Int Immunopharmacol [Internet]. 2020 Dec 1 [cited 2021 Jan 13];89(Pt B). Available from: https://pubmed.ncbi.nlm.nih.gov/33075713/
- Dastan F, Saffaei A, Haseli S, et al. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Int Immunopharmacol [Internet]. 2020 Nov 1 [cited 2021 Jan 13];88. Available from: https://pubmed.ncbi.nlm.nih.gov/32889241/
- Ramiro S, Mostard RLM, Magro-Checa C, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: Results of the CHIC study. Ann Rheum Dis [Internet]. 2020 Sep 1 [cited 2021 Jan 13];79(9):1143–1151. Available from: https://pubmed.ncbi.nlm.nih.gov/32719045/
- Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med [Internet]. 2021 Jan 1 [cited 2021 Apr 16];181(1):32–40. Available from: https://jamanetwork.com/
- Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. J Allergy Clin Immunol [Internet]. 2021 Jan 1 [cited 2021 Apr 16];147(1):72–80.e8. Available from: https://pubmed.ncbi.nlm.nih.gov/33010257/
- Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother [Internet]. 2021 Jan 1 [cited 2021 Jan 13];133. Available from: https://pubmed.ncbi.nlm.nih.gov/33378989/ 110825
- Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med [Internet]. 2020 Dec 17 [cited 2021 Jan 13];384(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33332779/ 20–30
- Zhao J, Cui W, Tian BP Efficacy of tocilizumab treatment in severely ill COVID-19 patients [Internet]. Vol. 24, crit care. BioMed Central Ltd; 2020 [cited 2021 Jan 13]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450680/ 1
- Berardicurti O, Ruscitti P, Ursini F, et al. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. Clin Exp Rheumatol [Internet]. 2020 Nov 1 [cited 2021 Jan 13];38(6):1247–1254. Available from: https://pubmed.ncbi.nlm.nih.gov/33275094/
- Strohbehn GW, Heiss BL, Rouhani SJ, et al. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther [Internet]. 2021 Mar 1 [cited 2021 Apr 16];109(3):688–696. Available from: https://pubmed.ncbi.nlm.nih.gov/33210302/
- Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med [Internet]. 2020 Dec 10 [cited 2021 Jan 13];383(24):2333–2344. Available from: https://pubmed.ncbi.nlm.nih.gov/33085857/
- Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial. BMJ [Internet]. 2021 Jan 20 [cited 2021 Apr 16];372. Available from: https://pubmed.ncbi.nlm.nih.gov/33472855/
- Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized with COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med [Internet]. 2021 Jan 1 [cited 2021 Apr 16];181(1):24–31. Available from: https://pubmed.ncbi.nlm.nih.gov/33080005/
- Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet [Internet]. 2021 May 1 [cited 2021 Sep 7];397(10285):1637–1645. Available from: http://www.thelancet.com/article/S0140673621006760/fulltext
- The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 New England Journal of Medicine . [Internet]. 2021 Feb 25 [cited 2021 Sep 7];384(16):1491–1502. [Internet]. 2021 Feb 25; ():.
- Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med [Internet]. 2021 Nov 1 [cited 2021 Dec 27];47(11):1258–1270. Available from: https://pubmed.ncbi.nlm.nih.gov/34609549/
- Gremese E, Cingolani A, Bosello SL, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine [Internet]. 2020 Oct 1 [cited 2021 Jan 13];27. Available from: https://pubmed.ncbi.nlm.nih.gov/33043284/
- Montesarchio V, Parella R, Iommelli C, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer [Internet]. 2020 Aug 11 [cited 2021 Jan 13];8(2). Available from: /pmc/articles/PMC7418768/?report=abstract
- Benucci M, Giannasi G, Cecchini P, et al. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients [Internet]. J Med Virol. 2020[cited 2021 Jan 13];92(11):2368–2370. Available from. John Wiley and Sons Inc. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300861/
- Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study. Ann Rheum Dis [Internet]. 2020 Oct 1 [cited 2021 Jan 13];79(10):1277–1285. Available from: https://pubmed.ncbi.nlm.nih.gov/32620597/
- Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med [Internet]. 2021 May 1 [cited 2021 Dec 27];9(5):522–532. Available from: https://pubmed.ncbi.nlm.nih.gov/33676590/
- León López R, Fernández SC, Limia Pérez L, et al. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): Protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. BMJ Open [Internet]. 2020 Nov 14 [cited 2021 Jan 13];10(11). Available from: https://pubmed.ncbi.nlm.nih.gov/33191263/
- Garcia-Vicuña R, Abad-Santos F, González-Alvaro I, et al. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): A structured summary of a study protocol for a randomised controlled trial [Internet]. Vol. 21, Trials. BioMed Central Ltd; 2020 [cited 2021 Jan 13]. Available from: https://pubmed.ncbi.nlm.nih.gov/32907638/ 1.
- Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev . [Internet] 2021 Mar 18 [cited 2021 Apr 16];3. Available from: https://pubmed.ncbi.nlm.nih.gov/33734435/
- Sivapalasingam S, Lederer DJ, Bhore R, et al. A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19. medRxiv [Internet]. 2021 Oct 28 [cited 2021 Dec 27];2021.May.13.21256973. Available from: https://www.medrxiv.org/content/https://doi.org/10.1101/2021.05.13.21256973v4
- Caricchio R, Abbate A, Gordeev I, et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA [Internet]. 2021 Jul 20 [cited 2021 Dec 26];326(3):230–239. Available from: https://pubmed.ncbi.nlm.nih.gov/34283183/
- Kyriazopoulou E, Panagopoulos P, Metallidis S, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife [Internet]. 2021 Mar 8 [cited 2021 Apr 16];10. Available from: https://pubmed.ncbi.nlm.nih.gov/33682678/
- Mariette X, Hermine O, Resche-Rigon M, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med [Internet]. 2021 Mar 1 [cited 2021 Apr 16];9(3):295–304. Available from: https://pubmed.ncbi.nlm.nih.gov/33493450/
- Derde LPG, Gordon AC, Mouncey PR, et al. Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv [Internet]. 2021 Jun 25 [cited 2021 Dec 26];2021.Jun.18.21259133. Available from: https://www.medrxiv.org/content/https://doi.org/10.1101/2021.06.18.21259133v2
- Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med [Internet]. 2021 Oct 1 [cited 2021 Dec 26];27(10):1752–1760. Available from: https://pubmed.ncbi.nlm.nih.gov/34480127/
- Aomar-Millán IF, Salvatierra J, Torres-Parejo Ú, et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. Intern Emerg Med [Internet]. 2021 Jan 5 [cited 2021 Jan 13]; Available from: https://pubmed.ncbi.nlm.nih.gov/33400157/
- Iglesias-Julián E, López-Veloso M, De-la-torre-ferrera N, et al. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. J Autoimmun [Internet]. 2020 Dec 1 [cited 2021 Jan 13];115. Available from: https://pubmed.ncbi.nlm.nih.gov/32843231/
- Langer-Gould A, Smith JB, Gonzales EG, et al. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis [Internet]. 2020 Oct 1 [cited 2021 Jan 13];99:291–297. Available from: https://pubmed.ncbi.nlm.nih.gov/32768693/
- Navarro-Millán I, Sattui SE, Lakhanpal A, et al. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis Rheumatol [Internet]. 2020 Dec 1 [cited 2021 Jan 13];72(12):1990–1997. Available from: https://pubmed.ncbi.nlm.nih.gov/32602262/
- Aouba A, Baldolli A, Geffray L, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: Case series [Internet]. Ann Rheum Dis. 2020[cited 2021 Jan 13];79(10):1381–1382. Available from. BMJ Publishing Group. http://saintantoine.aphp.fr/score/
- Kaps L, Labenz C, Grimm D, et al. Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report. Clin Case Rep [Internet]. 2020 Dec 1 [cited 2021 Jan 13];8(12):2990–2994. Available from: https://pubmed.ncbi.nlm.nih.gov/33363865/
- Kooistra EJ, Waalders NJB, Grondman I, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit Care [Internet]. 2020 Dec 1 [cited 2021 Jan 13];24(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33302991/
- Cauchois R, Koubi M, Delarbre D, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A [Internet]. 2020 Aug 11 [cited 2021 Jan 13];117(32):18951–18953. Available from: /pmc/articles/PMC7430998/?report=abstract
- Balkhair A, Al-Zakwani I, Al Busaidi M, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis [Internet]. 2021 Feb 1 [cited 2021 Jan 13];103:288–296. Available from: https://pubmed.ncbi.nlm.nih.gov/33217576/
- Nemchand P, Tahir H, Mediwake R, et al. Cytokine storm and use of anakinra in a patient with COVID-19. BMJ Case Rep [Internet]. 2020 Sep 15 [cited 2021 Jan 13];13(9). Available from: https://pubmed.ncbi.nlm.nih.gov/32933914/
- Clark KEN, Collas O, Lachmann H, et al. Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series. Rheumatol Adv Pract [Internet]. 2020 [cited 2021 Jan 13];4(2). Available from: https://pubmed.ncbi.nlm.nih.gov/32964179/
- Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol [Internet]. 2020 Jul 1 [cited 2021 Jan 13];2(7):e393–400. Available from: https://pubmed.ncbi.nlm.nih.gov/32835245/
- Pontali E, Volpi S, Antonucci G, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol [Internet]. 2020 Jul 1 [cited 2021 Jan 13];146(1):213–215. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211718/
- Borie R, Savale L, Dossier A, et al. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS One [Internet]. 2020 Dec 1 [cited 2021 Jan 13];15(12). Available from: https://pubmed.ncbi.nlm.nih.gov/33326457/
- Calò Carducci FI, De Ioris MA, Agrati C, et al. Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. Front Pediatr [Internet]. 2020 Nov 30 [cited 2021 Jan 13];8. Available from: https://pubmed.ncbi.nlm.nih.gov/33330276/
- Bozzi G, Mangioni D, Minoia F, et al.Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort studyJ Allergy Clin Immunol2020[cited 2021 Jan 13]; Available from; https://pubmed.ncbi.nlm.nih.gov/33220354/
- Pontali E, Volpi S, Signori A, et al. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J Allergy Clin Immunol [Internet]. 2021 Apr 1 [cited 2021 Apr 16];147(4). Available from: https://pubmed.ncbi.nlm.nih.gov/33556464/ 1217–1225
- Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology [Internet]. 2020 Aug 1 [cited 2021 Jan 13];159(2):481–491.e3. Available from: https://pubmed.ncbi.nlm.nih.gov/32425234/
- Gianfrancesco M, Hyrich KL, Hyrich KL, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis [Internet]. 2020 Jul 1 [cited 2021 Jan 13];79(7):859–866. Available from: https://pubmed.ncbi.nlm.nih.gov/32471903/
- Winthrop KL, Brunton AE, Beekmann S, et al. SARS CoV-2 infection among patients using immunomodulatory therapies. Ann Rheum Dis [Internet]. 2020 Aug 5 [cited 2021 Jan 13];80(2):annrheumdis-2020-218580. Available from: https://www
- Nørgård BM, Nielsen J, Knudsen T, et al.Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort studyBr J Clin Pharmacol2020[cited 2021 Jan 13]; Available from; https://pubmed.ncbi.nlm.nih.gov/33098713/
- Bezzio C, Manes G, Bini F, et al. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. Gut [Internet]. 2020 Jun 17 [cited 2021 Jan 14]; gutjnl-2020-321760. Available from: http://gut.bmj.com/ 70 3 623–624.
- Stallmach A, Kortgen A, Gonnert F, et al. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure - A cautionary case series [Internet]. Vol. 24, crit care. BioMed Central; 2020 [cited 2021 Jan 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366555/ 1
- Fakharian A, Barati S, Mirenayat M, et al. Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial. Int Immunopharmacol [Internet]. 2021 Oct 1 [cited 2021 Dec 26];99. Available from: https://pubmed.ncbi.nlm.nih.gov/34426106/ 107961
- Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol [Internet]. 2020 Jun 5 [cited 2021 Jan 19];5(48). Available from: https://pubmed.ncbi.nlm.nih.gov/32503877/
- Thibaud S, Tremblay D, Bhalla S, et al. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19 [Internet]. Vol. 190, Br J Haematol. Blackwell Publishing Ltd; 2020 [cited 2021 Jan 19]. p. e73–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276870/ 2
- Lin AY, Cuttica MJ, Ison MG, et al. Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review. eJHaem. Internet]. 2020 Nov [cited 2021 Jan 19];1(2):596–600. Available from. ;():. https://pubmed.ncbi.nlm.nih.gov/33043320/
- Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients [Internet]. Blood. 2020[cited 2021 Jan 19];135(21):1912–1915. Available from. American Society of Hematology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243149/
- Peterson D, Damsky W, King B The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [ Internet]. Vol. 82, J Am Acad Dermatol. Mosby Inc.; 2020 [cited 2021 Jan 19]. p. e223–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144601/ 6
- Agrawal M, Brenner EJ, Zhang X, et al. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. Inflamm Bowel Dis [Internet]. 2020 Dec 16 [cited 2021 Jan 19];XX. Available from: https://academic.oup.com/ibdjournal/advance-article/doi/https://doi.org/10.1093/ibd/izaa303/6039067
- Jacobs J, Clark-Snustad K, and Lee S Case Report of a SARS-CoV-2 Infection in a Patient with Ulcerative Colitis on Tofacitinib]. Vol. 26 7 , Inflammatory Bowel Diseases. ; 2020 []. p. e64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197538/
- Yan B, Freiwald T, Chauss D, et al.SARS-CoV2 drives JAK1/2-dependent local and systemic complement hyper-activationRes Sq2020[cited 2021 Jan 19]; Available from; https://pubmed.ncbi.nlm.nih.gov/32702726/
- Mortara A, Mazzetti S, Margonato D, et al. Compassionate use of Ruxolitinib in patients with SarsCov‐2 infection not on mechanical ventilation. Short‐term effects on inflammation and ventilation. Clin Transl Sci [Internet]. 2021 Jan 6 [cited 2021 Jan 19]; cts.12971. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1111/cts.12971 14 3 1062–1068
- Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol [Internet]. 2020 Jul 1 [cited 2021 Jan 19];146(1):137–146.e3. Available from: https://pubmed.ncbi.nlm.nih.gov/32470486/
- Capochiani E, Frediani B, Iervasi G, et al. Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol. Front Med [Internet]. 2020 Aug 4 [cited 2021 Jan 19];7. Available from: https://pubmed.ncbi.nlm.nih.gov/32850921/
- Vannucchi AM, Sordi B, Morettini A, et al.Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational studyLeukemia2020[cited 2021 Jan 19]; Available from; https://pubmed.ncbi.nlm.nih.gov/32814839/
- Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 [[cited 2021 Jan 19]; Available from];35(2):485–493. Internet: https://pubmed.ncbi.nlm.nih.gov/33414483/
- Betelli M, De Stefano F, and Tedeschi A Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid Eur Jcase reports Intern Med . [Internet]. 2020 [cited 2021 Jan 19];7(11):001938. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33194871
- D’Alessio A, Del Poggio P, Bracchi F, et al.Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumoniaLeukemia2020[cited 2021 Jan 19]; Available from; https://pubmed.ncbi.nlm.nih.gov/33173161/
- Innes AJ, Cook LB, Marks S, et al. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection [Internet]. Br J Haematol. 2020[cited 2021 Jan 13];190(4):e198–200. Available from. Blackwell Publishing Ltd. https://pubmed.ncbi.nlm.nih.gov/32593183/
- Foss FM, Rubinowitz A, Landry ML, et al. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib [Internet]. Clin Lymphoma Myeloma Leukemia. 2020[cited 2021 Jan 19];20(11):720–723. Available from. Elsevier Inc. https://pubmed.ncbi.nlm.nih.gov/32727701/
- Cantini F, Goletti D, Petrone L, et al. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review [Internet]. Drugs Adis. 2020 [cited 2021 Jan 19];80(18):1929–1946. Available from: https://pubmed.ncbi.nlm.nih.gov/33068263/
- Rosas J, Liaño FP, Cantó ML, et al. Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. Reumatol Clin [Internet]. 2020 [cited 2021 Jan 19]; Available from: https://pubmed.ncbi.nlm.nih.gov/33358361/
- Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med [Internet]. 2021 Mar 4 [cited 2021 Jan 19];384(9):795–807. Available from: http://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2031994
- Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, et al. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology [Internet]. 2020 Oct 6 [cited 2021 Jan 19];60(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33020836/ 399–407
- Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest [Internet]. 2020 Dec 1 [cited 2021 Jan 19];130(12):6409–6416. Available from: https://pubmed.ncbi.nlm.nih.gov/32809969/
- Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact [Internet]. J Infect W.B. Saunders Ltd. 2020 [cited 2021 Jan 19];81(2):318–356. Available from: https://pubmed.ncbi.nlm.nih.gov/32333918/
- Cingolani A, Tummolo AM, Montemurro G, et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection [Internet]. 2020 Oct 1 [cited 2021 Jan 13];48(5):767–771. Available from: https://pubmed.ncbi.nlm.nih.gov/32642806/
- FDA. Fact sheet for healthcare providers emergency use authorization (EUA) of baricitinib [Internet]. [cited 2021 Apr 16]. Available from: www.lillytrade.com
- Marconi VC, Ramanan AV, de BS, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med Internet]. 2021 Sep [cited 2021 Sep 7];0. Available from. http://www.thelancet.com/article/S2213260021003313/fulltext
- Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med [Internet]. 2021 Jul 29 [cited 2021 Dec 27];385(5):406–415. Available from: https://pubmed.ncbi.nlm.nih.gov/34133856/
- Yuan M, Xu X, Xia D, et al. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis. Shock [Internet]. 2020 Nov 1 [cited 2021 Jan 20];54(5):638–643. Available from: https://pubmed.ncbi.nlm.nih.gov/32496422/
- Tang X, Feng YM, Ni JX, et al. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration [Internet]. 2021 Feb 1 [cited 2021 Apr 16];100(2):116–126. Available from: https://pubmed.ncbi.nlm.nih.gov/33486496/
- Jamaati H, Hashemian SMR, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol [Internet]. 2021 Apr 15 [cited 2021 Apr 16];897. Available from: https://pubmed.ncbi.nlm.nih.gov/33607104/ 173947
- Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. Internet]. Vol. 3, ; 2006 [cited 2021 Jan 20]. p. 1525–1531. Available from; :. :https://pubmed.ncbi.nlm.nih.gov/16968120/
- Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med [Internet]. 2018 Mar 15 [cited 2021 Jan 20];197(6):757–767. Available from: https://pubmed.ncbi.nlm.nih.gov/29161116/
- Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza [Internet]. Cochrane Database Syst Rev. 2016 [[cited 2021 Jan 20]. Available from];2016. John Wiley and Sons Ltd https://pubmed.ncbi.nlm.nih.gov/26950335/
- The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. [Internet]. 2020 Jul 17 [cited 2021 Jan 20]; NEJMoa2021436. Available from; 384(8):693–704.https://pubmed.ncbi.nlm.nih.gov/32678530/
- Sterne JAC, Murthy S, Diaz JV, et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis. J Am Med Assoc [Internet]. 2020 Oct 6 [cited 2021 Jan 20];324(13):1330–1341. Available from: https://jamanetwork.com/
- Ma S, Xu C, Liu S, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials [Internet]. Signal Transduct Target Ther. Springer Nature. 6(1):2021 [cited 2021 Apr 16]. Available from; https://pubmed.ncbi.nlm.nih.gov/33612824/
- Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. J Am Med Assoc. Internet]. 2020 [cited 2021 Jan 20];324(13):1307–1316. Available from;: https://pubmed.ncbi.nlm.nih.gov/32876695/
- Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. J Am Med Assoc. Internet]. 2020 [cited 2021 Jan 20];324(13):1317–1329. Available from;: https://pubmed.ncbi.nlm.nih.gov/32876697/
- Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis [Internet]. 2021 Apr 10 [cited 2021 Apr 16];21(1):337. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33838657
- Leung YY, Yao Hui LL, and Kraus VB Colchicine-Update on mechanisms of action and therapeutic uses]. Vol. 45 3 , Seminars in Arthritis and Rheumatism. ; 2015 p. 341–350. Available from: https://pubmed.ncbi.nlm.nih.gov/26228647/
- Martínez GJ, Robertson S, Barraclough J, et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc [Internet]. 2015 Aug 24 [cited 2021 Jan 12];4(8):e002128. Available from: https://pubmed.ncbi.nlm.nih.gov/26304941/
- Chen I-Y, Moriyama M, Chang M-F, et al. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome. Front Microbiol [Internet]. 2019 Jan 29 [cited 2021 Jan 12];10(JAN):50. Available from: https://www.frontiersin.org/article/https://doi.org/10.3389/fmicb.2019.00050/full
- Brunetti L, Diawara O, Tsai A, et al. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J Clin Med [Internet]. 2020 Sep 14 [cited 2021 Jan 11];9(9):2961. Available from: /pmc/articles/PMC7565543/?report=abstract
- Salah HM, Mehta JL Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19. Am J Cardiol [Internet]. 2021 Apr [cited 2021 Apr 16];145:170. Available from: /pmc/articles/PMC7894200/
- Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: A retrospective cohort study [Internet]. Vol. 24, crit care. BioMed Central; 2020 [cited 2021 Jan 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358561/ 1
- Sandhu T, Tieng A, Chilimuri S, et al. A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe covid-19 infection. Can J Infect Dis Med Microbiol Internet]. 2020 [cited 2021 Jan 11];Available from. ;2020:1–9. https://pubmed.ncbi.nlm.nih.gov/33133323/
- Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis [Internet]. 2020 Oct 1 [cited 2021 Jan 11];79(10):1286–1289. Available from: https://doi.org/10.1136/annrheumdis-2020-217712
- Vrachatis DA, Giannopoulos GV, Giotaki SG, et al. Impact of colchicine on mortality in patients with COVID-19. A meta-analysis. Hell J Cardiol [Internet]. 2021 Jan 6 [cited 2021 Jan 11]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1109966620302852 62 5 374–377
- Haslak F, Yildiz M, Adrovic A, et al. Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int [Internet]. 2020 Sep 1 [cited 2021 Jan 11];40(9):1423–1431. Available from: https://pubmed.ncbi.nlm.nih.gov/32661928/
- Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv [Internet]. 2020 Aug 12 [cited 2021 Jan 11];.20169573. Available from: https://doi.org/10.1101/2020.08.06.20169573
- Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Network Open [Internet]. 2020 Jun 1 [cited 2021 Jan 11];3(6):e2013136. Available from: https://pubmed.ncbi.nlm.nih.gov/32579195/
- Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: The case for colchicine [Internet]. Ann Rheum Dis. BMJ Publishing Group. 2020 cited 2021 Jan 11;0:1–8. Available fromhttps://doi.org/10.1136/annrheumdis-2020-219174
- Piantoni S, Patroni A, Toniati P, et al. Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease. Rheumatology [Internet]. 2020 Jul 1 [cited 2021 Jan 11];59(7):1769–1770. Available from: https://academic.oup.com/rheumatology/article/59/7/1769/5848955
- Kow CS, Hasan SS. Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19. Rheumatol Int. Springer Science and Business Media Deutschland GmbH. 2021;[Internet]. Vol. 1, . ; [cited 2021 Jan 11]. p. 1. Available from] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778475/
- Tardif J-C, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med [Internet]. 2019 Dec 26 [cited 2021 Jan 12];381(26):2497–2505. Available from: https://www.nejm.org/doi/full/https://doi.org/10.1056/NEJMoa1912388
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression [Internet]. Lancet Lancet Publishing Group. 2020 [cited 2021 Jan 12];395(10229):1033–1034. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270045/
- Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial. RMD Open [Internet]. 2021 Feb 4 [cited 2021 Apr 16];7(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33542047/ e001455
- Della-Torre E, Della-Torre F, Kusanovic M, et al. Treating COVID-19 with colchicine in community healthcare setting [Internet]. Clin Immunol Academic Press Inc. 2020 [cited 2021 Jan 11]; 217:108490. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1521661620304782
- Tardif J-C, Bouabdallaoui N, L’Allier PL, et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. medRxiv [Internet]. 2021 Jan 27 [cited 2021 Sep 7]. Available from. https://www.medrxiv.org/content/https://doi.org/10.1101/2021.01.26.21250494v1
- Group PTC, Dorward J, Yu L-M, et al. Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. medRxiv [Internet]. 2021 Sep 23 [cited 2021 Dec 27];21263828. Available from: https://www.medrxiv.org/content/https://doi.org/10.1101/2021.09.20.21263828v1
- Group RC, Horby PW, Campbell M, et al. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Internet]. 2021 May 18 [cited 2021 Sep 7];21257267. Available from: https://www.medrxiv.org/content/https://doi.org/10.1101/2021.05.18.21257267v1